Full Press Release Details
Cronos Group Inc. Announces Third Quarter
Increased Revenues 186%
and Kilograms Sold 213% Year-over-Year
Licensed and Commenced
Cultivation in Building 4
Announced Landmark Partnership
with Ginkgo Bioworks to Produce Cultured Cannabinoids
Recreational Brand Spinach
Created NatuEra, the
First Cannabis CMO in Latin America and Received Non-Psychoactive Plant License
TORONTO, Nov. 13, 2018 /CNW/ - Cronos
Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company"), today announced
financial results for the third quarter ended September 30, 2018.
"We are encouraged with our third quarter
results, which reflect the meaningful progress we are making on our strategic initiatives. In the quarter, we announced a number
of landmark partnerships to expand our reach beyond the flower and beyond Canada and launched our second differentiated recreational
cannabis brand," said Mike Gorenstein, CEO of Cronos Group. "The recent legalization of cannabis sales for adult recreational
use in Canada was a watershed moment for our industry and our Company. We are energized by the opportunities this creates for Cronos
Group in Canada and look forward to leading the industry forward responsibly."
"As excited as we are about this milestone
and our participation in this new market, it's truly just the beginning. Cronos Group is building an innovative global cannabinoid
company. The opportunities for our Company extend across the globe as regulations evolve and markets open. The recent initiatives
we launched with Gingko Bioworks and Technion are great examples of how we intend to use innovation and our growing intellectual
property portfolio to develop new applications for cannabinoids across a range of categories. We are proud of all that we accomplished
this quarter, and we are focused on executing on our strategic plan to drive growth and value creation for our shareholders, partners
and consumers," concluded Mike Gorenstein.
Third Quarter 2018 Business Highlights
Construction of Building 4, a 286,000 sq. ft. purpose-built
indoor production facility built to GMP standards, is complete. Building 4 is expected to become fully operational in phases. The
facility commenced cannabis cultivation after receiving its license on August 31, 2018. The first harvest from Building 4 is expected
Cronos Group and Ginkgo Bioworks, Inc. ("Ginkgo")
announced a landmark partnership to produce cultured cannabinoids through fermentation that are identical to those extracted from
the cannabis plant. The research and development partnership is focused on producing large volumes of eight target cannabinoids,
including rare cannabinoids, from custom yeast strains by leveraging existing fermentation infrastructure (i.e. breweries or pharmaceutical
contract manufacturing operations) without incurring significant capital expenditures to build new cultivation and extraction facilities.
The Company will fund certain research and development and foundry expenses expected to be approximately US$22.0 million, subject
to the achievement of certain milestones. In addition, tranches of Cronos Group's common shares will be issued to Ginkgo, upon
Ginkgo's demonstration that the microorganisms are capable of producing the target cannabinoids for less than US$1,000 per kilogram
of pure cannabinoid at a scale of greater than 200 liters. The Company targets three years to achieve the equity milestones for
the eight target cannabinoids.
In August 2018, the Company announced a 50/50 strategic
joint venture with an affiliate of Agroidea SAS ("AGI"), a leading Colombian agricultural services provider with
over 30 years of research, development and production operations and expertise managing industrial scale horticultural operations
in Colombia. This partnership establishes a newly formed entity, NatuEra S. r.l. ("NatuEra"), in Colombia
that will develop, cultivate, manufacture and export cannabis-based medical and consumer products for the Latin American and global
markets. NatuEra is the cannabis industry's first CMO in Latin America, with plans to allow the growing number of cannabis brands
to outsource their cultivation and manufacturing. NatuEra plans to develop its initial cultivation and manufacturing operations
with a purpose-built, GMP-standard facility located in Cundinamarca, Colombia. NatuEra was granted a license to cultivate non-psychoactive
cannabis plants for the production of seeds for planting and the manufacture of derivative products. This license has an effective
term of five years from August 31, 2018. NatuEra is awaiting the grant of licenses to cultivate psychoactive cannabis and manufacture
derivative products. Commencement of operations at the facility will be subject to obtaining the remaining appropriate licenses
under applicable law.
Cronos Group launched its mainstream recreational brand
Spinach . A fun, lighthearted and playful brand, Spinach is focused on offering Farm-To-Bowl products that
bring friends together and make experiences more enjoyable. This brand has High Expectations and is geared towards a wide
range of consumers that don't take life too seriously and are looking for entertaining, fun ways to enhance activities.
In July 2018, Cronos Group announced a 50/50 strategic
joint venture with a group of investors led by Bert Mucci, a leading Canadian large-scale greenhouse operator. The entity created
by this new partnership, Cronos Growing Company Inc. ("Cronos GrowCo"), expects to construct an 850,000 square
foot, purpose-built, GMP-standard greenhouse on approximately 100 acres of land to be acquired by Cronos GrowCo in Kingsville,
Ontario. Once fully operational, the greenhouse is expected to produce up to 70,000 kilograms of cannabis annually. Construction
of the greenhouse has commenced and is expected to be complete in the second half of 2019.
Cronos Group entered into a supply agreement with one of
the largest cannabis companies in the world by revenues in the first quarter of 2018, Cura Cannabis Solutions ("Cura").
Cura signed a five year take-or-pay supply agreement to purchase a minimum of 20,000 kilograms of cannabis per annum from Cronos
GrowCo after Cura receives all necessary licenses from Health Canada. Cura also expects to build its proprietary, state-of-the-art
extraction facility on a parcel of land owned by Cronos Group in the heart of Okanagan Valley, British Columbia.
Business Highlights Subsequent to Third
In October 2018, the Company announced it had entered into
a sponsored research agreement with the Technion Research and Development Foundation of the Technion - Israel Institute of Technology
("Technion") to explore the use of cannabinoids and their role in regulating skin health and skin disorders. The
preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions: acne, psoriasis
On October 17, 2018, Canada became the first G7 country
and the second country in the world to legalize cannabis sales for adult recreational use. The Company is actively engaged in this
distribution channel and is currently selling dried cannabis, pre-rolls and cannabis oils to Ontario, British Columbia, Nova Scotia
and Prince Edward Island, which collectively represent over 50% of the Canadian population. The Company expects to secure additional
provincial listings as more of its production capacity comes online, which will allow the Company to adequately service additional
Third Quarter 2018 Financial Highlights
Third quarter 2018 revenues totaled $3.8 million, as compared
to $1.3 million for the third quarter of 2017, representing an increase of $2.4 million, or 186%. Kilograms of cannabis sold increased
213% in the third quarter from 164 kilograms in the third quarter of 2017 to 514 kilograms in the third quarter of 2018. The main
drivers associated with the increase in revenues and the increase in kilograms sold are increased production capacity and increased
volumes sold through the domestic medical and international channels, as well as initial shipments into the domestic adult-use
recreational market.
The Company continues to see strong growth in cannabis
oil sales, which represented 29% of total revenue in the third quarter of 2018.
The Company will host a conference call and live audio webcast on Tuesday, November 13, 2018 at 8:30 a.m. EST to discuss third
quarter 2018 results. The call will last approximately one hour. Instructions for the conference call are provided below:
Live Audio Webcast: https://thecronosgroup.com/investor-relations
Toll-free dial-in number: (888) 231-8191
International dial-in number: (647) 427-7450
Conference ID: 8084817
Additionally, an audio replay of the conference
call will be available two hours after the call's completion and until 11:59 p.m. EST on November 27, 2018. Instructions for the
audio replay are provided below:
Toll-free dial-in number: (855) 859-2056
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across five continents. Cronos
Group operates two wholly-owned Canadian license holders: Peace Naturals Project Inc., which was the first non-incumbent medical
cannabis license granted by Health Canada, and Original BC Ltd., which is based in the Okanagan Valley, British Columbia. Cronos
Group has multiple international production and distribution platforms and intends to continue to rapidly expand its global footprint